EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The 125th Anniversary of Aspirin—The Story Continues

Oliver Werz iD, Hans Stettler iD, Christoph Theurer, Jens Seibel

Pharmaceuticals · 28.03.2024 · 17 (4) · 437

DOI: 10.3390/ph17040437 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 28.03.2024. Verfasst von Oliver Werz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich Schiller University Jena, 07743 Jena, Germany. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer Vital GmbH, Leverkusen, Germany.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The year 2024 marks the 125th anniversary of aspirin, still one of the most frequently used drugs worldwide. Despite its veritable age, it is still relevant in pharmacotherapy and its use has spread to new areas over time. Due to aspirin’s multiple pharmacological actions unified in one single molecule (i.e., analgesic, antipyretic, anti-inflammatory, antithrombotic, and antiviral effects), it continues to attract considerable attention in the scientific community and is subject to intense basic and clinical research. In fact, recent results confirmed aspirin’s potential role as an antiviral drug and as an agent that can block harmful platelet functions in inflammatory/immunological processes. These features may open up new horizons for this ancient drug. The future of aspirin looks, therefore, bright and promising. Aspirin is not yet ready for retirement; on the contrary, its success story continues. This 125th anniversary paper will concisely review the various therapeutic uses of aspirin with a particular emphasis on the latest research results and their implications (e.g., use as an antiviral agent). In addition, the reader is provided with future perspectives for this remarkable drug.

Schlagwörter

Stichwörter der Autor:innen

acetylsalicylic acidanniversaryantiviralaspirinfuturehistory

Autor:innen und Institutionen

  • Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich Schiller University Jena, 07743 Jena, Germany.
  • Bayer Consumer Care AG, Peter Merian-Strasse 84, 4002 Basel, Switzerland.
  • Bayer Vital GmbH, Kaiser-Wilhelm-Allee 70, 51373 Leverkusen, Germany.

ORCID-Profile: Oliver Werz, Hans Stettler

Förderung

  • Bayer Vital GmbH, Leverkusen, Germany

Zitieren

APA

Werz, O., Stettler, H., Theurer, C., & Seibel, J. (2024). The 125th Anniversary of Aspirin—The Story Continues. Pharmaceuticals, 17(4), 437. https://doi.org/10.3390/ph17040437

Vancouver

Werz O, Stettler H, Theurer C, Seibel J. The 125th Anniversary of Aspirin—The Story Continues. Pharmaceuticals. 2024;17(4):437. doi:10.3390/ph17040437

BibTeX
@article{Werz2024,
  author = {Werz, Oliver and Stettler, Hans and Theurer, Christoph and Seibel, Jens},
  title = {The 125th Anniversary of Aspirin—The Story Continues},
  journal = {Pharmaceuticals},
  year = {2024},
  volume = {17},
  number = {4},
  pages = {437},
  doi = {10.3390/ph17040437}
}
Kostenlos starten →